Sun Pharma slips 5% as US court bars it from launching alopecia drug

Quick Summary:

The management has already spelled out contingency plans in case of an unfavourable verdict, during its Q2 earnings call.

One of those is the possibility of an out of court settlement before the patent expiry in December 2026.

The stock has corrected 10 per cent from its record high level of Rs 1,960.20 hit on September 30, 2024.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: India

Topics: Markets Sun Pharma owner US Court Leqselvi Sun Pharmaceutical Industries share price Sun Pharma share price Sun Pharma leqselvi launch injuction Baldness treatment Q2 Sun Pharma ICICI Securities Sun Pharma news Preliminary injunction

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-04 @ 10:10:15 (2 weeks ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 396 words

Reading Time: 3 minutes read

Sentences: 14 lines

Sentence Length: 29 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 23388740

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 309 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 8 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions